The anticancer activity of T‐DXd in patients with HER2‐mutant NSCLC was initially studied in a dose‐expansion, phase I trial across various advanced solid tumors by Tsurutani et al.118. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.